Published on
June 20, 2025
- 05:36 GMT
Diasome Pharmaceuticals Completes Enrollment in Phase 2b OPTI-2 Trial of HDV-Insulin Lispro for Type 1 Diabetes
Phase 2b OPTI-2 trial to assess liver-targeted insulin’s ability to reduce hypoglycemia and improve postprandial control using Dexcom G7 CGM data CLEVELAND, OH, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
